Illumina was founded in 1998 and is headquartered in San Diego, California. Illumina, Inc. engages in the development, manufacture, and marketing of integrated systems for the analysis of genetic variation and biological function. Its instrumentation products include Genome Analyzer II, an instrument for high-throughput sequencing using Illumina sequencing by synthesis technology; iScan System, a high-resolution imaging instrument to scan BeadArray based assays; and BeadXpress Reader, a low- to mid-multiplex, high-throughput instrument for readout of assays. The company's consumables comprise Standard Sequencing Kit, a reagent used for sequencing by synthesis chemistry on the Genome Analyzer; Paired-End Genomic DNA Sample Prep Kit, a streamlined library preparation kit to generate 200—500 kb insert paired-end reads; InfiniumHD Whole-Genome BeadChips comprising Human1M-Duo, Human610-Quad, Human660W-Quad, and HumanCytoSNP-12, which are multi-sample DNA analysis microarrays that interrogate up to 1.2 million markers per sample; iSelect Custom Genotyping BeadChips that are customer designable SNP genotyping arrays for 6,000 to 200,000 markers; and Whole-Genome Gene Expression BeadChips, which are multi-sample expression profiling arrays with up-to-date content for human, mouse, and rat.

LipoScience, Inc. company was founded in 1994 by its chief scientific officer, Dr. James Otvos. LipoScience, Inc. company's primary product, the NMR LipoProfile, uses nuclear magnetic resonance (NMR) therapy to analyze blood samples and assess the levels of lipoprotein particles in the bloodstream. (Such particles contain cholesterol, and detection of them can help pinpoint cardiovascular risks.) The LipoProfile differs from other cholesterol tests in that it does not require physical separation of the particles. LipoScience markets the LipoProfile and other traditional diagnostic tests through a direct sales force to health care providers and research labs.

Laboratoires Arkopharma's products offer a glimpse of modern worries: ampoules of fat reducers, tablets to help quit smoking, creams to tackle cellulite, and capsules to alleviate anxiety and stress. Arkopharma produces plant-derived OTC drugs and nutritional supplements. The company also manufactures homeopathic remedies and cosmetics. Arkopharma markets its products under a variety of brands, including Arkocaps, Arkofluide, 4.3.2.1. Slim, Phyto Soya, and Plante System. Subsidiaries of the company can be found in Australia, Europe, and the UK. The founding Rombi family controls the company through its holding company Imarko.

Neogen Corporation was founded in 1981 and is based in Lansing, Michigan. Neogen Corporation (Neogen), together with its subsidiaries, develops, manufactures and markets a line of products dedicated to food and animal safety. The Company operates in two primary business areas: the food safety segment and the animal safety segment. The Company’s food safety segment consists primarily of diagnostic test kits and complementary products marketed by sales personnel in the North American, Mexico, the United Kingdom and other parts of Europe, and by distributors elsewhere to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed. Neogen’s animal safety segment is engaged in the development, manufacture and marketing of pharmaceuticals, rodenticides, disinfectants, vaccines, veterinary instruments, topicals and diagnostic products for the worldwide animal safety market. In May 4, 2009, Neogen acquired International Diagnostic Systems Corporation.

Jiangbo Pharmaceuticals, Inc. (Jiangbo), formerly Genesis Pharmaceuticals Enterprises, Inc., is a holding company. The Company operates, controls and owns the pharmaceutical business of Laiyang Jiangbo Pharmaceutical Co., Ltd. (Laiyang Jiangbo). Laiyang Jiangbo researches, develops, manufactures, markets and sells pharmaceutical products and health supplements in the PRC. Laiyang Jiangbo produces tablets, capsules, granules, syrup and electuary for both Western medical drugs and Chinese herbal-based medical drugs. Approximately 35% of its products are Chinese herbal-based drugs and 65% are Western medical drugs. In February 2009, the Company acquired Shandong Hongrui Pharmaceutical Factory (Shandong Hongrui).

Biosite Incorporated company's diagnostic products include its Triage Drugs of Abuse Panel and Triage TOX Drug Screen which are used in hospital settings to test for commonly abused drugs. Its other diagnostic products include tests to detect intestinal parasites, diagnose congestive heart failure, and measure the biomarkers associated with stroke. The Biosite Discovery program is a collaborative research effort to identify protein markers for a variety of ailments. Medical diagnostics firm Inverness Medical Innovations acquired Biosite in 2007.

Quarks may be the basic building blocks of matter, but it's a fundamental unit of biology -- genes -- that Quark Pharmaceuticals is interested in. The drug development company is using cutting-edge RNA interference (RNAi) technology to develop small-interfering RNA (siRNA) molecules, or drugs that inhibit targeted genes from producing proteins associated with certain diseases. Its lead product RTP801i-14, which it has licensed to Pfizer, aims to treat wet age-related macular degeneration (a cause of blindness in the elderly). Quark Pharmaceuticals is developing other candidates for ailments such as acute renal (kidney) failure, hearing loss, and dyslipidemia (a metabolic syndrome).

Exelixis, Inc. company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California. Exelixis, Inc. discovers and develops small molecule drugs for the treatment of cancer, and various metabolic and cardiovascular disorders. Its products include XL184, a Phase 3 clinical trial compound that inhibits MET, RET, and VEGFR2, which drive tumor growth and vascularization, as well as Phase 1b/2 clinical trials compounds, including XL147 that targets phosphoinosotide-3 kinase (PI3K); and XL765, which targets PI3K and mTOR, kinases in the PI3K signaling pathway. The company has various compounds in phase 1 clinical trials, including XL518, a small molecule inhibitor of the MEK, a component of the RAS/RAF/MEK/ERK signaling pathway; XL228, which targets insulin-like growth factor type 1 receptor, an RTK in a range of human tumors; XL019 that inhibits JAK2, a cytoplasmic tyrosine; XL139, which inhibits activation of Hedgehog signaling; XL413, a small molecule inhibitor of the serine-threonine kinase CDC7; and XL888, a synthetic inhibitor of HSP90, a chaperone protein that promotes the activity and stability of a range of regulatory proteins, including kinases. In addition, its preclinical and clinical development stage products that are out-licensed to third parties for the development and commercialization include XL880, an inhibitor of MET and VEGFR2; XL281, which targets RAF, a cytoplasmic serine/threonine kinase; XL652 targeting liver X receptors, which modulate genes involved in regulation of lipid and cholesterol homeostasis; XL550, a non-steroidal mineralocorticoid receptor; and FXR Program that targets Farnesoid X Receptor, a bile acid receptor. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; GlaxoSmithKline; Wyeth Pharmaceuticals; and Daiichi-Sankyo.

Pharsight wants to shorten the path to market for tomorrow's pharmaceutical breakthroughs. The company's software and consulting services aim to take some of the guesswork out of the drug development process for pharmaceutical and biotech firms, helping them choose the most promising drug candidates, to design effective clinical trials, and to keep up with regulatory reporting. Pharsight's WinNonlin and WinNonMix applications, for instance, analyze research and clinical data to help companies develop appropriate dosing regimens for clinical trials. And its consulting services help them make key strategy decisions about the future of development programs. Pharsight was acquired by Tripos in 2008.

Cornerstone Therapeutics Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for the respiratory market in the United States. Its marketed products include SPECTRACEF for the treatment of mild to moderate infections, such as community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, pharyngitis and tonsillitis, and uncomplicated skin and skin-structure infections; ZYFLO CR for the prevention and chronic treatment of asthma in adults and children 12 years of age or older; and ALLERX Dose Pack products, which are oral tablets for the temporary relief of symptoms associated with allergic rhinitis.Cornerstone Therapeutics company also markets HYOMAX line of products, which consist of generic formulations of four antispasmodic medications containing the API hyoscyamine sulfate, an anticholinergic for functional intestinal disorders to reduce symptoms, such as those seen in mild dysenteries and diverticulitis; and BALACET 325, APAP 325, and APAP 500 for the relief of mild to moderate pain. In addition, its products under development include SPECTRACEF Once Daily for acute bacterial exacerbations of chronic bronchitis with COPD; SPECTRACEF Suspension for pharyngitis and tonsillitis, and acute otitis media; CRTX 058 for temporary relief of symptoms associated with allergic rhinitis; and CRTX 067 and CRTX 069 for temporary relief of symptoms associated with cough, and upper respiratory symptoms associated with allergies or a cold.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.